Zorenko Y. M., Pavlova O. O., Gorbach T. V., Martynova S. M.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

Abstract. Introduction. It is known that the synaptic dysfunction a key to many neurodegenerative diseases, including Alzheimer’s disease. It has been shown that not only amyloid plaques but also hypoxia and mitochondrial dysfunction are crucialfor the synaptic dysfunction. At the same time, it is poorly known the role of these factors in the mechanisms of Alzheimer’s type dementia of various origins. The aim of the study: to determinate the role of hypoxia and mitochondrial dysfunction in the mechanisms of the experimental Alzheimer’s type dementia development induced by different ways in rats, as well as the possibility of correction of this condition by mesenchymal stem cells. Materials and methods. 32 male WAG rats weighing 180-250 g (n=8 in each group) for 14 and 28 days received intraperitoneal injections of an aqueous solution of sodium nitrite at a dose of 50 mg/kg (gr. N-14, N-28with nitrite-induced dementia) and a solution of scopolamine butylbromide at a dose of 1 m/ kg (gr. SC-14, SC-28 with scopolamine-induced dementia). Other 32 male rats of gr.NS-14, NS-28, SCS-14, SCS-28 were intravenously administered with mesenchymal stem cells (MSCs) after injections of sodium nitrite and scopolamine. Control rats (gr.C, n=16) received sodium chloride injections according to the same experimental design. Rats were sacrificed 14 days after the last injection of MSCs. The concentration of 2,3-diphosphoglycerate in blood erythrocytes (2,3-DFG, μmol/l), acetylcholine (AСh, μg/g) and ATP (μmol/g) – in brain homogenates, cardiolipin (nmol/mg protein) – in mitochondria of brain tissue were determined by using spectrophotometer. Results. The level of 2,3-DFG (nitrite model) was dose-dependently increased in rats gr. N-14, N-28.In rats with scopolamine-induced dementia, an increase in this indicator was observed only twice in gr. SC-28 in comparison with gr. C, but was less pronounced than in gr. N-28. The ATP and cardiolipin concentration in all experimental groups was reduced compared to gr. C. It should be noted that in gr. N-14, N-28 the cardiolipin content in mitochondria was significantly lower than in gr. SC-14, SC-28. The ACh level in gr. N-14, N-28, SC-14 almost did not change, while in gr. SC-28 was reduced as much as possible compared to that in gr. C. The introduction of MSCs improved energy metabolism, reduced hypoxia, normalized the Ach level, but the cardiolipin content was not restored to the control level. Conclusions. A common factor in the pathogenesis of both studied models was mitochondrial dysfunction. The initial factor of mitochondrial dysfunction in the nitrite model was hemic hypoxia and endothelial dysfunction, and in scopolamine – acetylcholine deficiency with subsequent amyloid deposition in brain tissue and blood vessels. Correction of Alzheimer’s type dementia of various genesis is possible with the mesenchymal stem cells introduction. Intravenous administration of MSCs improved mitochondrial function, but without their full recovery.

dementia, hypoxia, mitochondria, stem cells, rats.

1. Flannery PJ, Trushina E. Mitochondrial dynamics and transport in Alzheimer’s disease. Mol Cell Neurosci. 2019;98:109–20.
2. Putti R, Sica R, Migliaccio V, Lionetti L. Diet impact on mitochondrial bioenergetics and dynamics. Front Physiol. 2015;6:109.
3. Lionetti L, Mollica MP, Donizzetti I, Gifuni G, Sica R, Pignalosa A, et al. High-lard and high-fish-oil diets differ in their effects on function and dynamic behaviour of rat hepatic mitochondria. PLoS One. 2014;9(3):e92753.
4. Manoharan S, Guillemin GJ, Abiramasundari RS, Essa MM, Akbar M, Akbar MD. The role of reactive oxygen species in the pathogenesis of Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease: A mini review. Oxid Med Cell Longev. 2016;2016:8590578.
5. Cid-Castro C, Hernández-Espinosa DR, Morán J. ROS as regulators of mitochondrial dynamics in neurons. Cell Mol Neurobiol. 2018;38(5):995–1007.
6. Manczak M, Kandimalla R, Fry D, Sesaki H, Reddy PH. Protective effects of reduced dynamin-related protein 1 against amyloid betainduced mitochondrial dysfunction and synaptic damage in Alzheimer’s disease. Hum Mol Genet. 2016;25(23):5148–66.
7. Zhang L, Trushin S, Christensen TA, Bachmeier BV, Gateno B, Schroeder A, et al. Altered brain energetics induces mitochondrial fission arrest in Alzheimer’s Disease. Sci Rep. 2016;6:18725.
8. Darshi M, Mendiola VL, Mackey MR, Murphy AN, Koller A, Perkins GA, et al. ChChd3, an inner mitochondrial membrane protein, is essential for maintaining crista integrity and mitochondrial function. J Biol Chem. 2011;286(4):2918–32.
9. Cai Q, Tammineni P. Mitochondrial aspects of synaptic dysfunction in Alzheimer’s disease. J Alzheimers Dis. 2017;57(4):1087–103.
10. Lin M-Y, Sheng Z-H. Regulation of mitochondrial transport in neurons. Exp Cell Res. 2015;334(1):35–44.
11. Solaini G, Baracca A, Lenaz G, Sgarbi G. Hypoxia and mitochondrial oxidative metabolism. Biochim Biophys Acta. 2010;1797(6.7):1171–7.
12. Ham PB, Raju R. Mitochondrial function in hypoxic ischemic injury and influence of aging. Prog Neurobiol. 2017;157:92–116.
13. Joshi AS, Thompson MN, Fei N, Hüttemann M, Greenberg ML. Cardiolipin and mitochondrial phosphatidylethanolamine have overlapping functions in mitochondrial fusion in Saccharomyces cerevisiae. Journal Biol Chem. 2012;287(21):17589–97.
14. Nikolayeva OV, Pavlova OO, Lukyanova YM, Gubina-Vakulik GI, Gorbach TV, vynakhid. KHNMU, patentovlasnyk. Sposib modelyuvannya dementsiyi altsgeymerivskogo typu sudynnogo pokhodzhennya u shchuriv. Patent Ukrainy № 141759. 2020 Kvit 27. [in Ukrainian].
15. Dejko R, Shtrigol S, Laryanovskaya Y, Gorbach TV, Gubina-Vakulik G, Devyatkina N, et al. Chronic blockade of central muscarinic receptors in rats reproduces primary pathogenetic links of Alzheimer’s disease. Aktualʹni problemy suchasnoyi medytsyny. 2017;17(3):13-25. [in Ukrainian].
16. Meshkova NP. Praktykum po byokhymyy. M.: yzdatelstvo moskovskogo unyversyteta; 1979. 430 s. [in Russian].
17. Pyatikop V, Msallam MA Jr, Shchegelskaya E, Kutovoy I, Gubina-Vakulik G. Migration features of labeled bone marrow mesenchymal stem cells in rats with modeled Parkinson-like syndrome. Ukrayin neyrokhirurhichnyy zhurnal. 2014;3:42–8. [in Ukrainian].
18. Mranova YS. Opredelenye 2,3 DFG y ATF v erytrotsytakh. Laboratornoe delo. 1975;7:652–654. [in Russian].
19. Trubytsyna YE, Drozdov VN, Lazebnyk LB, Lychkova AE, izobretatel’. Sposob opredelenyya atsetylkholyna. Patent Rosii № 2256920. 2003 Sent 15. [in Russian].
20. Prokhorova MY. Metody byokhymycheskykh yssledovanyy (lypydnyy y energetycheskyy obmen). Lenyngrad: Yzdatelstvo Lenyngrad unyversyteta; 1982. 272 s. [in Russian].
21. Lemeshko VV. Mitokhondrii. Akkumulyatsiya energii i regulyatsiya fermentativnykh protsessov. Moskva: Nauka; 1977. Chast’ 1, Sokhranenye funktsyonalnoy aktyvnosty mytokhondryy pry glubokom zamorazhyvanyy; s. 5-11. [in Russian].
22. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37(8):911–7.
23. Bartlett GR. Phosphorus assay in column chromatography. J Biol Chem. 1959;234(3):466–8.
24. Salminen A, Kauppinen A, Kaarniranta K. Hypoxia/ischemia activate processing of Amyloid Precursor Protein: impact of vascular dysfunction in the pathogenesis of Alzheimer’s disease. J Neurochem. 2017;140(4):536–49.
25. Lukyanova YM. Influence of chronic administration of sodium nitrite on morphofunctional state of brain in rats. Ukr ž med bìol ta sportu. 2019;4(6):52–9. [in Ukrainian].
26. Grette Lydon R. Neurotransmitters and Neuromodulators. CRC Press; 2020. Chapter 10, Cholinergic neurons and memory: An historical perspective and overview of current research; p. 197–232.
27. Gorbach TV, Nakonechna OA, Tkachenko AS, Shcholok TS, Onikova AO. Levels of thyroid hormones and indices of energy metabolism in the cerebral cortex of rats with experimental Alzheimer’s disease. Neurophysiology. 2018;50(3):159–65.
28. Beach TG, Kuo Y-M, Spiegel K, Emmerling MR, Sue LI, Kokjohn K, et al. The cholinergic deficit coincides with Aβ deposition at the earliest histopathologic stages of Alzheimer disease. J Neuropathol Exp Neurol. 2000;59(4):308–13.
29. Ferreira-Vieira TH, Guimaraes IM, Silva FR, Ribeiro FM. Alzheimer’s disease: Targeting the cholinergic system. Current Neuropharmacol. 2016;14(1):101–15.
30. Grimaldi M, Marino SD, Florenzano F, Ciotta MT, Nori SL, Rodriquez M, et al. β-Amyloid-acetylcholine molecular interaction: new role of cholinergic mediators in anti-Alzheimer therapy? Future Med Chem. 2016;8(11):1179–89.
31. Muhammad T, Ali T, Ikram M, Khan A, Alam SI, Kim MO. Melatonin rescue oxidative stress-mediated neuroinflammation/ neurodegeneration and memory impairment in scopolamine-induced amnesia mice model. J Neuroimmune Pharmacol. 2019;14(2):278–94.
32. de la Monte SM, Tong M. Mechanisms of nitrosamine-mediated neurodegeneration: potential relevance to sporadic Alzheimer’s disease. J Alzheimers Dis. 2009;17(4):817–25.
33. Safar MM, Arab HH, Rizk SM, El-Maraghy SA. Bone marrow-derived endothelial progenitor cells protect against scopolamine-induced Alzheimer-like pathological aberrations. Mol Neurobiol. 2016;53(3):1403–18.
34. Qin C, Lu Y, Wang K, Bai L, Shi G, Huang Y, et al. Transplantation of bone marrow mesenchymal stem cells improves cognitive deficits and alleviates neuropathology in animal models of Alzheimer’s disease: a meta-analytic review on potential mechanisms. Transl Neurodegener. 2020;9(1):20.

«Bulletin of problems biology and medicine» Issue 1 (159), 2021 year, 66-72 pages, index UDK 616.89-008.454-001.8-092.9-08:602.9:591.476

10.29254/2077-4214-2021-1-159-66-72